Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.

摘要: The importance of epidermal growth factor receptor (EGFR) gene mutation has been recognized in nonsmall cell lung cancer (NSCLC), requiring the standardization screening system including kind samples. Here, we examined EGFR status 61 pleural fluid samples from NSCLC cases using direct sequencing, nonenriched PCR, mutant-enriched PCR and peptide nucleic acid-locked acid (PNA-LNA) clamp assay. assay detected 16 mutant cases. Among them, failed to detect 3 Regarding discrepancy between PNA-LNA assays, exon19-deletions were only by no difference at L858R mutation. There was results sequencing We also correlated with clinical outcome gefitinib-treated 29 mutations present 10 cases, revealing 7 partial response change (NC). In wild-type revealed NC 9 progressive disease. responders significantly more frequent among than (p < 0.0001). Overall survival = 0.0092) progression-free 0.018) longer wild-type. summary, evaluated utility 4 assays that showed some discrepancies arising designs assays. As importance, can be a biomarker for favorable © 2006 Wiley-Liss, Inc.